Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Laboratories, |
RCV001509122 | SCV001715662 | uncertain significance | not provided | 2019-07-15 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV003284361 | SCV003971935 | uncertain significance | Inborn genetic diseases | 2023-04-27 | criteria provided, single submitter | clinical testing | The c.2023C>G (p.P675A) alteration is located in exon 19 (coding exon 19) of the PHKA1 gene. This alteration results from a C to G substitution at nucleotide position 2023, causing the proline (P) at amino acid position 675 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |